Atossa’s leading product candidate, Endoxifen, is an active metabolite of tamoxifen

Breast Cancer and Breast Conditions: Endoxifen: Atossa’s leading product candidate, Endoxifen, is an active metabolite of tamoxifen. It is being developed for the treatment of breast cancer and for reducing breast density, which is a risk factor for breast cancer.Oral and Topical Formulations:The company is exploring both oral and topical formulations of Endoxifen to provide versatile treatment options for patients with different needs and preferences. Infectious Diseases: COVID−19 Therapies: In response to the COVID−19 pandemic, Atossa is developing AT−H201, a novel inhalation therapy aimed at improving lung function in COVID−19 patients and potentially mitigating the impact of the virus.Innovative Approaches: Atossa is leveraging its expertise to explore additional therapies for other infectious diseases, with a focus on innovative and effective treatment solutions.